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3OPPORTUNITIES FOR GROWTH
In March 2012, the Welsh Government launched ‘Science for Wales’, which set out a vision 
for where Wales should be heading in the future. Three Grand Challenge priority areas 
were identified where Wales has a track record for excellence. Life Sciences and Health
is one of these three Grand Challenge priority areas.
Considerable development has already occurred in this area, including the establishment
of the Life Sciences Sector Panel, Team, Hub, and Fund operating together with organisations 
like MediWales and the Institute of Life Science. There are several Life Sciences centres
of excellence within Welsh academia, and NISCHR provides a dynamic focus for NHS Wales 
R&D. The population of Wales is an appropriate size for R&D activities, and the centrally 
managed NHS IT infrastructure enables national level research. 
These infrastructure elements and knowledge bases create an outstanding R&D 
environment, but do not yet constitute an integrated pipeline of commercialisation that 
supports development from discovery through to clinical application. Wales now has
an excellent opportunity to ‘join the dots’ to create this environment within Life Sciences. 
In September 2012, Swansea University (in partnership with Cardiff University and 
MediWales) was tasked by the Welsh Government to lead a Knowledge Exchange Project 
(KEP) for the Welsh Life Sciences and Health area. The aim of the KEP programme was to 
increase interaction, develop more effective knowledge exchange mechanisms, and stimulate 
the formation and maintenance of long-term collaborative relationships between industry 
and academia.
We created Life Science Exchange as a process, not an organisation.  Our vision was to 
create a mechanism which could continuously poll all the stakeholders in Wales’ complex 
life science ecosystem, in a way that allowed all to be involved.  The object is to allow 
participants to interact with other stakeholder communities (clinical, academic, business, 
governmental), exchanging perspectives, and then to support them by thinking about how 
Wales could improve its performance. To provide focus, we streamed this work into groups 
representing Wales’ major subsectors.
This report draws on the primary focus group work conducted by the Life Science Exchange 
project and also reports on the outcomes from collaborative projects identified and facilitated. 
The aim is to provide stakeholder views of the sector and deliver key recommendations 
to policy makers (e.g. Welsh Government). We hope the report will influence and shape 
the thinking in determining a Life Sciences policy as well as further knowledge exchange 
support measures.
The Life Science Exchange is a beacon for how Wales should support its stakeholders, 
providing a process and resources for networking, knowledge exchange, and exploration of 
over £2 million in new opportunities. Moving forward, we hope to continue this excellence 
in our multi-disciplinary approach to the Life Sciences sector.
I would like to thank my fellow colleagues and partners of the Life Science Exchange for 
their continued support through the last two years, as well as the many stakeholders who 
took the time to attend our events and contribute to this process. 
I have great confidence in a bright future for the Welsh Life Sciences sector.
FOREWORD
David Ford
Professor of Health Informatics
Swansea University
The LIFE SCIENCE EXCHANGE
The aim of the Life Science Exchange is to identify and develop effective innovative academic, public and private 
sector knowledge exchanges that deliver the results and impacts necessary to effect economic change. The Life 
Science Exchange has been funded through the Academic Expertise for Business (A4B) programme. A4B is a 
programme of support funded by the Welsh Government and European Structural Funds aimed at providing a 
simplified, integrated package of support for knowledge transfer from academia to business. The aim of the overall 
programme is to promote a high value-added economy and to maximise the economic impact of academia and 
business through knowledge transfer and the creation of a stronger science, engineering and technology base with 
clear commercial potential. 
The project was overseen by an executive level Steering Group, comprising senior representatives of all stakeholder 
groups within the Life Sciences sector, including academia, business, NHS Wales, and Welsh Government. This group 
set the strategy for the project, agreeing the areas in which detailed research should be undertaken and the approach 
to be taken by the project team. The work of the Focus Groups and overall project management of the Life Science 
Exchange was undertaken by a small project team led by Professor David Ford.
EXECUTIVE SUMMARY
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PROJECT OUTCOMES
Each of the Focus Groups had unique characteristics and stakeholders, which are reflected in the diverse opportunities they 
identified. The organisations in the Neuroscience Group appeared to be more active in earlier stage research and development 
and recognised opportunities in enhancing Wales’ neuroscience research capacity. Those that have more of an industrial base 
(e.g. eHealth, Diagnostics, Medical Devices and Pharmaceuticals) focused their attention on NHS engagement, procurement 
and technology adoption. All of the summarised opportunities found in the table above were discussed in each Focus Group, 
however some were not identified as a recommendation for their respective subsector. The project also promoted networking 
and a ‘joined up’ working between all stakeholder groups, leading to the identification and facilitation of collaborative projects. 
This created a powerful stimulus for the existing Welsh Life Sciences sector and a potent incentive for inward investment 
by international companies, leading to significant benefits to the Welsh economy. Collaborative projects identified during 
either Focus Groups or stakeholder engagement were further developed in sandpit events (an intensive, interactive workshop 
designed to produce innovative research proposals) or through bespoke support. This has led to more than £2 million of 
funding being successfully secured on behalf of Life Science Exchange support.
Establishment of a new special interest group
Mapping, sector knowledge and communication
NHS Procurement and technology adoption
NHS engagement and clinical access
Growing a skilled and trained workforce
Enhanced research capacity
International conferences and marketing
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SUMMARISED OPPORTUNITIES
The six specialist areas (Diagnostics, eHealth, Medical Technology, Neuroscience, Pharmaceuticals, and Regenerative Medicine) 
were selected to encompass the twelve Life Sciences areas prioritised in ‘Science for Wales’. Six Focus Groups were established 
and included participants from academia, industry, the Welsh Government and NHS Wales. Each Focus Group was chaired 
by one of the partner institutions and addressed specific aspects of the Welsh Life Sciences sector to strengths, challenges, 
and opportunities identified in each specialty area. As an outcome of the Focus Groups, each produced a confidential report 
outlining the significant barriers in their respective areas, made recommendations to overcome them, and identified the 
stakeholder groups which needed to take action. Although Welsh Government and NHS Wales staff attended the Focus 
Groups, as this project was funded from the A4B programme, many of the recommendations are from the academic and 
buisness perspective. Furthermore, a second outcome was a stakeholder-driven mapping exercise for each area of focus. These 
detailed reports and mapping exercises have been supplied to the Welsh Government’s Life Sciences Sector Team and the Life 
Sciences Sector Panel to inform policy and strategy. They will be made available to quintessential stakeholders by the Welsh 
Government upon request. This Life Science ‘Opportunities for Growth’ report has softened and abbreviated the confidential 
recommendations into ‘opportunities’. Descriptions for each opportunity can be found in the following sections of this report. 
To provide a global overview of the opportunities identified in the Focus Groups, they have been categorised and summarised 
into the table below – each opportunity represented by a coloured dot.
Funder Institution Amount
TSB, Small Business Research Initiative (SBRI) ABMU Health Board £800,000
WG, Health Technology and Telehealth Fund AliveCore, ABMU Health Board £772,208
NISCHR/NIHR i4i Confidential until money secured ~£400,000
Welsh Government A4B Digital Health Conference £50,000
Betsi Cadwallder SBRI SymlConnect £40,000
TOTAL £2,062,208
FUNDING SECURED AND INVESTMENT INDUCED
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MEDICAL RESEARCH COUNCIL
REGENERATIVE MEDICINE PLATFORM
HEALTH CLOUD
NHS WALES PROCUREMENT
FINANCE & FUNDING
EPSRC BRIDGING THE GAP
FOCUS GROUPS AND SANDPITS DECEMBER 2012
JUNE 2014
MEDICAL TECHNOLOGY
DIAGNOSTICS
PHARMACEUTICALS
EHEALTH
REGENERATIVE MEDICINE
NEUROSCIENCE
STEERING GROUP
FOCUS GROUPS
SANDPIT EVENTS
ABERTAWE BRO MORGANNWG UHB
SMALL BUSINESS RESEARCH INITIATIVE
PHARMACEUTICAL SPECIAL INTEREST GROUP
TRANSCRANIAL MAGNETIC STIMULATION
DECEMBER 2013
The Life Science Exchange organised quarterly meetings for the 
Steering Groups and Focus Groups over the period of 24 months.  
Collaborative projects identified were supported by sandpit events to 
further develop the ideas.
JUNE 2013
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FOCUS
GROUP 
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Each of the six Life Science Exchange 
Focus Groups authored reports outlining 
their stakeholders’ perspectives.
The following sections highlight the key 
strengths, challenges, and opportunities 
identified in each specialty area.
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DIAGNOSTICS
Medical diagnostics are the technologies concerned with the determination of a disease or 
condition causing a person’s signs and symptoms. Technologies produced in Wales include 
in-vitro diagnostics, molecular diagnostics, medical imaging and eHealth. In-vitro diagnostic 
tests are typically used in health professional settings or for consumers to use at home. 
Molecular diagnostics are technologies used to analyse biological markers in the genome and 
proteome by applying molecular biology to testing. Diagnostic imaging covers the capturing 
and interpretation of images for the purpose of medical diagnosis. Diagnostic technologies 
in eHealth are concerned with the collection and aggregation of patient level health data 
for monitoring purposes. Companion diagnostics is a new field embedded in the strategy of 
personalised medicines and involves genetic tests which provide information on a person’s 
likelihood of developing a specific disease or if certain drug treatments work effectively.
Of the 207 life science companies based in Wales, 33 (16%) are medical diagnostics companies. 
In-vitro diagnostic technology is the largest sub sector with 16 companies (7% of the UK total).
The devolved Welsh NHS is a unique and important asset to the diagnostics sector, as a 
research collaborator, a customer and as a supplier of clinical expertise. While most companies 
introduce their new products into global markets, adoption by the NHS can be an important 
reference site for demonstration, and stepping stone to achieving international sales. The 
work of NISCHR, NISCHR AHSC and specifically Health Research Wales is credited with 
playing an important role in improving engagement between industry and clinical experts. 
The Welsh Cancer Bank is also regarded as an excellent resource that has simplified the 
process of accessing tissue samples.
Close collaboration between academic institutions and manufacturers is an important 
feature of the Welsh life science sector. MediWales is the networking organisation that 
supports collaboration between Industry, academic and clinical professionals. The new Welsh 
Government Life Science Hub is intended to bring together the sector under one roof. Work 
is being carried out to address skills gaps in the diagnostics sector. In South West and Mid 
Wales the Regional Learning Partnership has carried out a survey to identify skills needs in 
the sector while Cardiff University is discussing the introduction of ‘Education for Industry’ 
courses. The Life Science Exchange has established an ongoing life science skills group to 
identify areas of need in the Welsh life science sector. Business incubator facilities are offered 
by Swansea University and the Cardiff Medicentre and industrial ‘grow on’ space is available 
at the Sony UK site in Pencoed.
Assessment and adoption of new diagnostic technologies by the NHS across the UK is 
a concern for diagnostics companies producing innovative solutions. There is currently 
no equivalent to the pharmaceutical assessment and adoption process for diagnostics. 
The general shift in the NHS market towards adoption of higher throughput diagnostic 
solutions and full service third party provision could become a barrier to adoption of niche 
technological innovations. Access to patient and infectious disease samples is an issue for 
R&D led diagnostics companies. An inadequate supply of UK clinical samples has created a 
bottleneck in the industry.
The sector suffers from skills shortages in regulation, intellectual property, project 
management and practical laboratory skills. Undergraduate students are often unaware of 
the range of roles available in the diagnostics sector including sales, marketing and regulation. 
Regulatory skills are an area of particular need for diagnostics companies. The regulatory 
burden on diagnostics technology companies is increasing. For new companies and SMEs, 
this regulation is a major barrier to market entry. Regulation is also a barrier to international 
trade. Given the international nature of the diagnostics sector, this is a priority issue.
There is a feeling that current laboratory and manufacturing facilities that suit the needs of 
the diagnostics companies are inadequate to meet the growth aspirations of the sector. 
For many smaller companies another limiting factor to international trade is the cost of 
specialist cold chain logistics. Diagnostic tests are more price sensitive than drugs but drug 
distribution can dictate the pricing of specialist logistics.
OVERVIEW
STRENGTHS
CHALLENGES
9OPPORTUNITIES FOR GROWTH
Wales has the opportunity to lead the UK in the implementation of a formal diagnostic 
technology appraisal and adoption process. Alongside this process the Diagnostics Focus 
Group would like to work with clinical colleagues to identify and address ‘unmet clinical 
needs’ in the diagnostics sector. To this end a Diagnostics Special Interest Group (SIG) is 
proposed, potentially as part of ongoing Life Science Exchange activity and with the support 
of MediWales.
The Diagnostics Focus Group would strongly support the provision of ethical and appropriate 
access to anonymous patient samples for research and testing. A ‘bio bank’ created using a 
similar model to the Wales Cancer Bank is proposed. This specific recommendation reflects a 
wider opportunity for close NHS / Industry engagement.
Given the proportion of business done outside of Wales, companies stress the need to support 
international activity as a priority. A specific action is for companies to collaborate, with a 
view to reducing the cost of international trade for smaller companies and niche products, to 
share capacity and to negotiate prices of specialist cold chain distribution.
There is a need to raise awareness of career options in the sector to undergraduates and to 
provide specialist training in subjects such as intellectual property, project management and 
practical laboratory skills. Companies can work together to create a critical mass of applicants 
required to make the provision of part time courses in these subjects. There is a specific 
need to develop the regulatory skills required for the future. Government assistance in the 
provision of regulatory support and training would be a valuable service to businesses. The 
continuation of the Life Science Exchange Skills Initiative could be an overarching forum for 
collaboration in this area.
There is a need for appropriate laboratory and mixed-use business accommodation for 
diagnostic companies if sector growth is not to be curtailed by a lack of appropriate research, 
development and manufacturing facilities.
OPPORTUNITIES
TECHNOLOGY 
ADOPTION AND 
UNMET CLINICAL 
NEEDS
BIOBANK
INTERNATIONAL
SKILLS
FACILITIES
“The help given by the Life Science Exchange team in helping demystify Horizon funding has been 
timely, extremely helpful and very supportive. Such a support system is badly needed in this sector 
given how complex it is to access grant funding which helps sustain business development in Wales.”
– Louisa Harry-Thomas, Operations Manager, Acuitas Medical Ltd
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eHEALTH
The NHS Wales Informatics Service (NWIS) has adopted the new definition for eHealth in 
Wales developed by the eHealth Industries Innovation (ehi2) Centre, which is: eHealth is 
better healthcare and a healthier life through digital technology. Examples include health 
information networks, electronic health records, telemedicine services, wearable and portable 
personal health systems and many other information and communication technology (ICT)-
based tools assisting disease prevention, diagnosis, treatment and follow up.
In a written Cabinet Statement on 23 April 2014, Mark Drakeford, Minister for Health and 
Social Services, announced a refresh on Welsh Government policy regarding eHealth and 
Care in Wales. He stated, “Our opportunity now is to focus on how eHealth and Care can help 
us to manage demand, empower us to take a more active role in decisions about our health 
and care, and deliver better quality services in the most effective and efficient way”.
 
A feasibility study performed in 2011 by ehi2 based out of Swansea University identified 70+ 
companies operating within Wales that were or had the intention to enter, the emerging 
market of eHealth. This multi-billion dollar global opportunity was seen by all as a major 
opportunity for Welsh businesses and also, if Wales were to leverage its major assets in the 
area – its university-based expertise, and its local NHS - Welsh companies could enter the UK 
and international markets with a significant competitive advantage. 
Wales has competitive strengths in the eHealth sector which spans University, NHS and 
industrial sectors. Particular strengths lie in health informatics, big data, and associated 
Research Council-funded centres of excellence. Key eHealth companies in Wales specialise 
in healthcare data capture, management, and extraction; clinical decision support; and 
early warning tools. Wales has significant assets in a devolved NHS, areas of health 
research excellence in a number of universities and strengths in the life sciences sector. 
Wales’ success in the development of a single electronic patient record and the secure 
anonymised information linkage database makes it an attractive location for medical trials 
and epidemiological work. Wales also boasts a range of support institutions including, but 
not limited to, eHealth Industries Innovation Centre (ehi2), the Electronic and Software 
Technologies Network for Wales (ESTNet), and MediWales. These groups provide key 
guidance to and act as a voice for the eHealth sector in Wales.
In order to realise the potential of Wales as a leader in eHealth innovation, it is essential 
that the development of eHealth products and services is supported in a co-ordinated and 
consistent fashion at every stage of their development. Availability of funding, access to 
academic facilities and expertise and clear guidance on market requirements and technical 
standards are all important in supporting innovation. In particular, being able to secure input 
and collaboration from NHS Wales at appropriate points from initial concept, through design 
and up to and including adoption of new innovations for market testing within an NHS 
environment is essential.
Many of the issues discussed in the Focus Groups refer to the need to increase access to 
NHS Wales at both a pre and post procurement stage of product development. Whilst 
Wales represents a very small part of the global health market, products which have been 
developed in partnership with NHS clinicians and tested within NHS premises (either 
on a pre-procurement or post procurement basis) carry a great deal of credibility in the 
international health market and have a significantly improved potential for international 
commercialisation. The Welsh NHS as a market is small, but the benefits to companies in 
being able to develop products which are suitable for adoption within it are significant. 
There are equivalent benefits to NHS Wales in encouraging collaboration too – addressing 
development of products and services to meet current needs, access to free or reduced cost 
products and services and potential IP shares from new innovations which go on to break into 
international markets. 
OVERVIEW
STRENGTHS
CHALLENGES
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Annual life science research priority strategy: Life Science Exchange eHealth focus group 
members questioned whether research and development in health informatics (and Life 
Science as a whole) was sufficiently co-ordinated. Too often research and innovation activities 
are designed and developed within single organisations, based on their perceptions of 
priorities and requirements, without wider linking to the sector as a whole. This has a number 
of disadvantages, including duplication of effort and development of solutions which are 
not required, not fit for purpose or do not satisfy an unmet clinical need. The Life Science 
Exchange group has suggested the need for a joined up strategy across the whole Life Sciences 
sector (encompassing government, NHS, Academia and the private sector). This strategy 
would identify agreed research priority areas every year, and would focus the research effort 
within Wales around achieving these. Projects which addressed priority areas should be 
given a co-ordinated development pathway from initial concept, through development to final 
trial in an NHS environment.
NHS Wales procurement processes are a significant issue for eHealth SMEs operating and 
innovating in Wales. NHS Wales is understandably keen to ensure that it works with 
companies which are reputable, stable and able to support NHS contracts into the future. 
However, current eligibility criteria effectively exclude small and medium sized companies 
from breaking into the market. The Life Science Exchange eHealth focus group members 
propose that NHS Wales (Shared Services Partnership) and NWIS should review the 
procurement models used in NHS Wales with the aim of creating a competitive environment 
for SMEs whilst still keeping risk within NHS procurements to an acceptable level.
Life Science Exchange stakeholders recognise that the technical and strategic direction of 
NHS Wales in relation to eHealth is driven by NWIS. Stakeholders suggested that NWIS 
should be involved in priority setting and identifying areas of unmet need (see above). The 
focus group welcomes the recent development of an NHS Standards toolkit, which provides 
a framework for companies to develop their software with existing data systems. The group 
feel that further work to promote this documentation and to embed it into research projects 
and development activities would be of great advantage to the sector. 
Stakeholders have shared concerns regarding a lack of sector knowledge throughout each 
of the Focus Groups. Generally, there is a need from all stakeholders for a global view of the 
resources, infrastructure, activities, events, products, and services that exist across the sector. 
In order to make the information about the Welsh Life Sciences sector clear to stakeholders, 
(all) information relevant to the sector should be available through one point of contact or 
organisation, which could also provide a comprehensive signposting service for accessing 
resources and support.
The size of Wales and its integrated NHS IT systems mean that it could be a fantastic place for 
clinical research, but more needs to be done to take advantage of this. Steps need to be taken 
to incentivise and promote clinical research, both at the institution and individual levels. 
SECTOR 
KNOWLEDGE AND 
COMMUNICATION 
“SymlConnect is an ILS based company dealing with ICT in healthcare. We found the LSE team 
very helpful, especially their events which supported our networking and knowledge transfer. The 
information flow, both during the events and via email communication, helped us understand and 
identify relevant opportunities. We are happy to announce that we recently won the Betsi Cadawaldr 
Heath Board’s SBRI challenge, which was facilitated by one these informed exchanges via the LSE.”
– Sabarna Mukhopadyay, CEO, SymlConnect
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MEDICAL TECHNOLOGY
The ‘medical technology’ sector includes companies whose major business activity involves 
the development, manufacture, or distribution of medical devices as defined by the European 
Union Medical Devices Directive (93/42/ECC) and companies who have significant activity in 
supplying specialist services to the medical technology sector.
Of the 207 life science companies based in Wales, 146 (71%) are medical technology companies. 
This figure represents around 5% of the companies based in the UK. The Welsh medical 
technology sector has a turnover of around £1,017m (6% of UK turnover) and employs around 
6,367 people (8% of UK employment). The sector has experienced significant growth in 
employment, with 2012-13 showing a growth of 8.6% in a single year. Annual turnover has 
increased since 2009 by a compound annual growth rate (CAGR) of 2.2%. The global market is 
expected to continue to grow at a rate of 4.5% per annum reaching global sales of £291bn by 2018.
A wide variety of medical technology products are produced in Wales. In-vitro Diagnostics 
is the largest sub sector with 16 companies (7% of the UK total). Assistive Technology is the 
second largest sub sector with 13 companies (4% of the UK total). The ICT and eHealth sub 
sector has 11 companies (6% of the UK total). Hospital hardware and single use equipment each 
have 10 companies (6% and 4% of the UK totals respectively). 16 companies provide specialist 
business services to the medical technology sector. Anecdotal evidence suggests that most 
medical products made in Wales are sold abroad.
Given the importance of access to clinical markets and expertise the key strength identified 
by the Medical Technology Focus Group is the role played by the NHS in Wales. One Focus 
Group member remarked, “They share the desire to see Welsh companies thrive.” A strong 
home NHS market is a prerequisite for UK and export sales. The Welsh NHS is recognised 
as being generally approachable and willing to help. Health Boards are increasingly more 
receptive to ideas that save time, reduce risk or increase capacity. 
It is felt that navigating the NHS procurement landscape is complicated, with numerous 
different routes for different products and companies who may use different tactics. Support 
for companies to navigate and take advantage of these opportunities is considered a priority 
for the sector. The Welsh NHS Shared Services Partnership is recognised for helping and 
guiding Welsh SMEs. Sell 2 Wales is also regarded as an excellent tool for accessing UK wide 
contracts.
It is noted by the Medical Technology Focus Group that a significant barrier to selling to 
the NHS is getting products to the approved vendor list. It is felt that there needs to be a 
mechanism for reducing the cost burden of approvals by the NHS so that it can undertake this 
activity faster and more often.
The unique roles of The Surgical Materials Testing Laboratory in Bridgend (SMTL) and CEDAR 
(NICE Evaluation Centre) are recognised and it is felt that these facilities could be further 
enlisted to help with assessment and approvals, which would also enhance the quality and 
perception of the Welsh medical technology sector.
Health Research Wales is recognised as presenting a significant opportunity to promote 
a strong clinical base for trials and testing to benefit both the population of Wales and 
indigenous businesses. The newly established Welsh Wound Innovation Centre may also 
contribute to the technology evaluation challenge.
OVERVIEW
STRENGTHS
CHALLENGES
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There is an opportunity for the Welsh NHS to introduce a clear and appropriate access point 
for new technology appraisal and adoption and to use procurement to encourage adoption 
of innovations where better patient outcomes or reduced costs can be achieved. Clinical 
specialists could be helped to engage with suppliers specific to their clinical specialty in order 
to address unmet technology needs.
Many of the needs expressed by the Medical Technology Focus Group concern access to 
information, specifically the need to map the route to market for medical technology in the 
NHS; a directory of qualified regulatory and QA consultants; information about international 
markets and data that demonstrates the extent and value of international trade carried out by 
Welsh companies; regular and timely notifications of regulatory changes; and more up-to-
date, timely, specific funding information.
 
Wales has a highly collaborative life science community. A number of novel suggestions were 
made by the Medical Technology Focus Group aimed at transforming this collaboration into 
tangible benefits. Closer interaction and a ‘bridging of cultural differences’ can be achieved 
between industry and NHS staff through a ‘job exchanges’ or an ‘embedded staff’ programme 
intended to facilitate NHS and industry staff spending time together in manufacturing and 
clinical settings.
Wales also has a strong industry base across a number of advanced manufacturing sectors 
with expertise that can translate into the medical technology sector. Cross sector collaboration 
between these groups should be facilitated and encouraged. Greater collaboration between 
the medical technology sector, commercial property agents, architects and builders to 
generate new mixed ‘fit for purpose’ facilities and support the projected growth in the sectors 
also proposed.
Each of these opportunities could be progressed through the continuation of a sub-sector 
Special Interest Group tasked with improving collaboration between academia, industry and 
the NHS.
The need for graduates whose skills meet the needs of the life science sector was expressed 
across all Focus Groups. In the Medical Technology Focus Groups, it was felt that there is 
a growing need for staff to be trained in GMP and that this could be delivered through 
engineering degree courses and bespoke courses for small businesses.
“The Life Science Exchange has been for us a key partner in starting our healthcare business in 
Wales, and part of the attraction to being at the Institute of Life Science. Life Science Exchange has, 
since the very beginning, proven knowledgeable and proactive in providing us with information 
about funding, key stakeholders and potential collaborators and supporting us in building our supply 
chain and facilitating business meetings, with a same or next day service, and often at very short 
notice when we have sent a request.
We would certainly recommend the Life Science Exchange to anyone in the life science industry and 
are counting on the service to help support our innovation and business growth needs across the 
Medical Device, Diagnostics and eHealth sectors, in these critical early stages of our business.”
– Dr. Ali Anjomshoaa, Managing Director, RhythmaCare
14
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NEUROSCIENCE
Neuroscience collectively encapsulates all branches of science and technology which aim 
to understand and interact with brain function. This is not restricted to fundamental 
neuroscience research using cellular or model systems or brain imaging, but also includes 
neuropsychiatric genetics, animal behaviour studies, cognitive neuroscience, and clinical 
neurosciences including psychiatry, neurology, neurosurgery and clinical/behavioural 
psychology. Clinically, neuroscience addresses conditions such as dementia, depression, 
schizophrenia, epilepsy, acquired brain injury (trauma and stroke), learning difficulties, 
autism and other neurodevelopmental disorders. All these areas place a huge burden on 
the Welsh, as well as global, health services and economy. These challenges will only be 
addressed with an integrated neuroscience research programme of the type that Wales is 
well placed to deliver.
Brain disorders present some of the major societal challenges and health care needs. This is 
a critical time where advances in basic neuroscience research can be combined with large  
clinical cohorts and technology development to address these issues. Wales is now at the 
beginning of a new period when our knowledge will take a big step forward, and lead to 
major innovations in health and social care and commercialisation in the next few years and 
decades. This brings with it the potential of curing some neurological and mental disorders 
and ameliorating the impact of many others, making it an important area to invest in.
Wales has internationally competitive strength in neuroscience that spans University, 
NHS and industrial sectors. Particular strengths lie in gene discovery and genomics, neuro 
imaging, medical technology, eHealth and is emerging in stem cell biology. Key anchor 
companies in Wales specialise in product manufacture and service provision for ‘big pharma’, 
including diagnostics, outsourcing of pharmacological testing and stem cell production. 
These could synergise well with the Universities, NHS-led research and local SMEs to offer 
robust foundations for the rapid expansion into a world-leading neuroscience research and 
development (R&D) community.
Early on the Welsh Neuroscience Focus Group identified the need for a more cohesive, 
collaborative, and country-wide approach to neuroscience research, development and 
commercialisation. A neuroscience network has been established in North Wales to ensure 
the development and delivery of high-quality services. Furthermore, the Focus Group 
identified five areas of high potential where Welsh neuroscience could use additional 
support, which span basic research, clinical translation and commercialisation. These areas 
include:
 
·         Genomic Medicine
·         Neuronal Stem Cell Biology
·         Systems Neurosciences
·         Neuroimaging, Neuromodulation, and Medical Technology
·         Informatics and eHealth
 
Furthermore, the continuation of Welsh excellence in neuroscience cannot be achieved 
without highly skilled people. Technical, research or managerial experience in the areas 
such as clinical provision, technology development and commercialisation or advanced skills 
in use of state-of-the-art neuroscience related technologies. The Welsh Neuroscience Focus 
Group has also recommended a sixth key area highlighting the need to be able to recruit, 
retain and train these individuals to achieve maximum delivery.
OVERVIEW
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A Welsh Neuroscience Network should be tasked to coordinate strategic capacity building, 
support integration across University, NHS and Industrial sectors within the region and 
promote Welsh neuroscience on the global stage. Public involvement and support is critical 
to the success of technology development, its medical and commercial application and for the 
total Welsh neuroscience research effort. The Network would provide an interface to inform 
and involve the public from the very beginning.
Wales needs to ensure that HPC Wales is fully utilised and integrated into the neuroscience 
research network, and that there are plans for sustainability and development in the 
long term. It may be necessary to consider grants and scholarships to individuals and 
organisations to promote the uptake of training. In addition, a professional network to 
support, develop and promote best practice may act to enhance integration across sectors and 
research areas. Finally, Sêr Cymru support could be prioritised to recruit a world-leader in 
neuro computation or genomics.
The capacity to carry out cost-effective high throughput sequencing is going to become vital 
across University research, NHS health services and commercial development. It is not only 
essential to develop and maintain this capacity for research and diagnostics, it also offers a 
clear opportunity to develop an information-based commercial regional export, particularly 
if this is coupled to the informatics and computing capacity described above.
The ability to differentiate human neurons from stem cells will have a major impact on 
research, health provision and commercial activity of the future, and research in this area 
is an emerging strength within Wales. The ultimate success of these high potential medical 
and life science technologies will require a competitive and supportive environment to 
maximise research capacity. A key component not present within Wales is a collective 
stem cell core facility and supply chain. This currently places the region at a competitive 
disadvantage to other global leaders.
A vital component of basic and preclinical research in University and commercial sectors is 
the ability to create and study in-vivo systems which model disease states. Recent technology 
advances have revolutionised our ability to create genetic models. These new approaches 
will reduce time and cost, whilst increasing sophistication in the types of models. Currently, 
there is no academic or commercial transgenic provision within Wales, or even the UK, 
and researchers currently import them from overseas. There is a growing need, and major 
opportunity, for generation and supply of these new in-vivo models within Wales.
The development of educational and training courses can provide and maintain the 
necessary skills and technical knowledge within the Welsh neuroscience sector to enhance 
the attractive pull of employment in industry, the NHS and universities. The Group 
propose the creation of a professional body of neuroscientists in Wales (aligned to the 
Welsh Neuroscience Network) which would develop a supportive community who would 
offer career development, including mentorship, and be a voice for all neuroscientists. 
Working with the Life Science Sector Hub, the professional body could monitor and advise 
on infrastructural and technical skills that are required for provision and competitiveness 
in technologies, such as PET and other imaging capabilities, informatics and cell-based 
therapies. 
ENHANCED 
CAPACITY FOR 
TRANSGENIC
IN-VIVO 
RESEARCH
SKILLED AND 
TRAINED 
WORKFORCE
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PHARMACEUTICALS
The term ‘pharmaceuticals’ is used collectively to encapsulate the institutions, departments, 
and people whose major activity is R&D of therapeutic products, which includes contract 
manufacturers, contract service organisations, and pharmaceutical wholesalers (as defined by 
the UK Department for Business, Innovation & Skills). This is not restricted to any particular 
technology, but does not include medical technology, medical biotechnology (i.e. biologics), 
or industrial biotechnology. Major clinical applications for pharmaceuticals include cancer, 
pain management, diabetes, hypertension, infection, and many others, which place a huge 
social and financial burden on Wales, as well as global health. These challenges will be best 
addressed with an integrated pharmaceutical R&D programme of the type that Wales is well 
placed to deliver.
In general, the pharmaceutical sector is a high-risk, high-value industry. It drives economic 
growth through ‘multiplier effects’ for employment, personal income, gross value added (GVA) 
and tax revenue, which also generates products that clearly benefit society and human health. 
For example, it has been shown that each job in the pharmaceutical sector provides almost 
double the average salary in the overall economy. Furthermore, pharmaceutical companies 
invest more than ten times the amount of R&D per employee than manufacturing industries 
overall. Research and development lies at the heart of the pharmaceutical industry, which 
invests more than any other industrial sector in the UK, with up to approximately £11.5 
million spent every day.
Wales has competitive strengths in the pharmaceutical sector that span university, 
NHS and industrial sectors. Particular strengths lie in drug discovery, clinical trials, and 
pharmaceutical services. Key anchor companies in Wales specialise in manufacturing and 
service provisions for ‘big pharma’, including cold chain logistics, manufacturing, drug 
delivery and clinical trials. These could synergise well with the universities, NHS-led research 
and local SMEs to offer robust foundations for the rapid expansion into the R&D community. 
Furthermore, Health Research Wales has identified opportunities to promote services of Welsh 
companies, universities and clinical trial units abroad.
Drug development is a global enterprise which has become concentrated into a small number 
of large multinational companies. This industry is at a crossroads with a common experience 
that the massive research costs are not always returned in the rate of development of new 
drugs; as a consequence ‘big pharma’ is withdrawing and downsizing in many areas including 
some which are considered areas of major unmet needs. There is a crisis in drug development 
for many important clinical fields. As a consequence, we are moving into a new era, where 
research collaboration and commercial outsourcing are the norm. Wales has never been a 
core part of the global pharmaceutical industry, and this global change in pharmaceutical 
strategy presents opportunities, rather than threats, for Welsh life sciences. Industrial sector 
activity in Wales relevant to pharmaceuticals encompasses sub-sector activity in contract 
drug development and manufacture. These will benefit from the development of new 
technologies and the need for large companies to outsource.
Wales has key strengths in the pharmaceutical sector which make it competitive on the 
world stage. Although this is the case, stakeholders shared concerns regarding a lack of sector 
knowledge throughout each of the Focus Groups.
In order to bring more pharmaceutical activity, a range of activities need to be supported 
through policy and initiatives, including international marketing, NHS Wales clinical access, 
medicines adoption, academic research translation, and recruitment, retention and training.
OVERVIEW
STRENGTHS
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Wales has considerable strengths in pharmaceutical manufacturing and providing clinical 
services. This is a key enabler for pharmaceuticals across the university, NHS and industry 
sectors and is the basis for strong therapeutics. Unified support to market these strengths 
internationally is required to grow the sector.
This enables efficient delivery across the community, primary care practices and hospitals. 
One of the unique selling points for Wales is that the NHS is devolved and fully integrated, 
with only ten NHS organisations, (seven regional Health Boards and three NHS Trusts). A 
major stepping stone in the drug development process is engaging with lead clinicians to guide 
pharmaceutical research and development, especially when executing regulated clinical 
trials. Steps need to be taken to incentivise and promote clinical research at the institution and 
individual levels within NHS Wales.
Poor uptake of new drugs in the UK in general, but Wales in particular, is becoming a 
significant barrier to Wales’ involvement in forthcoming commercial trials. NHS Wales and 
the All Wales Medicine Strategy Group should take into account first and foremost the impact 
on the patient (e.g. safety, efficacy) and cost-effectiveness to Wales, but should also consider 
the impact of their decisions regarding medicines adoption on the broader economic impact 
beyond healthcare budgets.
Academic research translation: Wales has a few strong case studies for translation of 
pharmaceutical innovations into commercial spinouts, e.g. Protides at Cardiff University. 
Nonetheless, the best pathway to commercialisation of a product or service is not always clear. 
Translation of pharmaceutical-related academic research into commercial products in Wales 
appears to require a cultural change. A greater level of academic, NHS Wales and industry 
collaboration needs to be forged.
Recruitment, retention and training: A key driver for future success is the ability to 
attract and retain highly skilled individuals. Whilst the university sector can focus on 
the development of training and education in key skills, retention requires growing the 
life sciences cluster to provide sustainable employment opportunities across NHS Wales, 
academia, and industrial partners.
SECTOR 
KNOWLEDGE 
“With the exciting current developments in the Welsh life sciences sector, it is important that 
initiatives such as the Life Science Exchange exist to bring key stake holders together on a regular 
basis to share experiences, knowledge and provide networking opportunities for the benefit of the 
whole sector.”
– John Roberts, Commercial Director, Penn Pharma
“Life Science Exchange has been extremely proactive in helping me build networks within Wales 
which would have been difficult to establish otherwise; also, their organised events are professional 
and well run, covering topics relevant to both to my business and the wider international life 
sciences arena. A welcome addition to Welsh Government’s support for the sector.”
– Hedley Rees, Managing Director, Pharmaflow
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REGENERATIVE MEDICINE
Regenerative medicine encapsulates a wide range of technologies and applications for the 
benefit of human health. According to the United Kingdom’s (UK) Technology Strategy Board 
(TSB), “Regenerative medicine is a broad term for innovative medical therapies that aim to 
replace or regenerate human cells, tissues or organs, to restore or establish normal function. 
It is not a single technology but a multidisciplinary approach, which can bring together 
tissue engineering, developmental and stem cell biology, gene therapy, cellular therapeutics, 
biomaterials (scaffolds and matrices), nanotechnology, bioengineering and chemical biology”. 
The UKTI Life Science Investment Organisation (LSIO) claims that regenerative medicine 
products surpassed $1 billion revenue in 2012 and are expected to grow to over $35 billion 
by 2019. According to the Medical Research Council, “Regenerative medicine is an emerging 
discipline that holds the promise of revolutionising patient care in the 21st century. The UK is a 
leading player globally in the science that underpins regenerative medicine.”
UK strengths in regenerative medicine include a world-leading research base, a unified 
healthcare system providing access to large numbers of patients and a highly organised blood 
transfusion and transplant service. The UK is also at the forefront of much of the underpinning 
science in this area and regenerative medicine has been recognised by the Government as one 
of ‘eight great future technologies’ in which the UK can be world-leading. The TSB identifies 
regenerative medicine as an important area of investment focus in 2008. An initial £8m 
commitment in 2009 leveraged an additional £10m of Government Strategic Investment, 
along with support from the Research Councils for development of a £21m programme for 
companies developing regenerative medicine and cell therapies during 2009-12. 
The Welsh University sector conducts world-leading research in the area of regenerative 
medicine. This is recognised by prestigious funding awards, for example, the Arthritis Research 
UK Biomechanics and Bioengineering Centre at Cardiff University and the UK Regenerative 
Medicine Platform’s “Disease/Systems focused award” at Swansea University. A major 
anchor company operating within the regenerative medicine field in Wales is GE Healthcare, 
located on a 30-acre site in Cardiff. It is involved in delivering breakthroughs in R&D and in 
biopharmaceutical manufacturing. Wales also hosts a series of SMEs focussed on cellular 
therapies, wound healing products and artificial tissues and organs. Lastly, Wales boasts a range 
of support institutions, including, but not limited to the Cardiff Institute of Tissue Engineering 
and Repair (CITER), Great Western Alliance (GW4) and MediWales.  These groups provide key 
guidance to and act as a voice for the regenerative medicine sector in Wales.
Although Wales accounts for nearly 5% of the United Kingdom’s (UK) population, the data 
from the UK Research Council & TSB’s A Strategy for UK Regenerative Medicine  (2012) state 
that Wales accounts for only 3% of the grant funding from UK Research Councils and TSB. 
Significant support will be required to grow the existing Welsh regenerative medicine sector 
and capture external opportunities. To show its support of regenerative medicine sector, on 
1 April 2014, Welsh Government announced it was allocating up to £500,000 to support the 
TSB’s funding competition for R&D projects designed to advance regenerative medicine and cell 
therapies. Economy Minister Edwina Hart stated, “Life sciences is one of our priority economic 
sectors and regenerative medicine is fast becoming an emerging area for Wales thanks to the 
presence of some world class researchers.”
Current strengths and activities in the regenerative medicine sector have high potential to 
deliver impact and growth. These will lead to new clinical therapeutic strategies and health 
delivery; new products and commercialisation opportunities, but also feedback as part of a 
virtuous circle to support and grow our capacity to deliver world-leading research excellence. 
The Life Science Exchange Regenerative Medicine Focus Group proposes five areas of high 
potential where the Welsh regenerative medicine sector could excel in basic research, clinical 
translation and commercialisation.
OVERVIEW
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The Life Science Exchange has identified a key opportunity in the regenerative medicine 
sector to improve on leadership, organisation, information dissemination, communication, 
interaction, and collaboration Wales-wide. It is proposed that a Welsh Regenerative Medicine 
Special Interest Group (RMSIG) be formed, tasked to coordinate strategic capacity building, 
support integration across University, NHS and Industrial sectors within the region and 
promote Welsh regenerative medicine on the global stage.
Stakeholders have shared concerns regarding a lack of sector knowledge throughout each 
of the Focus Groups. Generally, there is a need from all stakeholders for a global view of the 
resources, infrastructure, activities, events, products and services that exist across the sector. 
In order to make the information about the Welsh regenerative medicine sector clear to 
stakeholders, (all) information relevant to the sector should be available through one initiative 
rather than several.
A major stepping stone in the drug development process is engaging with lead clinicians 
to guide regenerative medicine research and development, especially when executing 
regulated clinical trials. Steps need to be taken to incentivise and promote clinical research 
at institution and individual levels. Support for Health Research Wales, clinician research 
time and research facilities is required to leverage the strengths of the Welsh regenerative 
medicine sector.
Wales has world-leading regenerative medicine research developing within academia and 
industry. Nonetheless, there is not always a clear idea of the route to commercialising a 
product or service. Translation of regenerative medicine-related academic research into 
commercial products in Wales requires greater support for collaborative research facilities, 
information (see Sector knowledge and communication, above) and commercial incentives.
Wales has considerable strengths in the regenerative medicine sector. This is a key enabler for 
regenerative medicine across the University, NHS and industry sectors and has the basis for 
strong therapeutics. Unified support to market these strengths internationally is required to 
grow the sector.
ENHANCED 
RESEARCH 
CAPACITY 
“Reconstructive Surgery and Regenerative Medicine is a rapidly expanding area of research 
excellence in the College of Medicine at Swansea University. The LSE has organised a set of 
workshops focused on regenerative medicine, exploring the strengths and opportunities in Wales. 
These have been very useful in understanding the landscape in Wales, and clearly seeing the 
strengths that Swansea’s College of Medicine and Centre for NanoHealth bring to this important 
area of growth in Wales.”
– Prof. Steve Conlan, Director, Centre for NanoHealth
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CASE
STUDIES
The Life Science Exchange delivered a range of events 
and activities throughout the two-year project. 
The following case studies provide a flavour of what 
the project has supported to date.
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10th February 2014
Waterton Centre Bridgend
Life Science Exchange and ABPI
This event was designed to gauge the strengths, weaknesses and opportunities within the 
pharmaceutical sector from the perspectives of Welsh academics, NHS representatives 
and pharmaceutical businesses. Attended by around forty delegates, the day included 
presentations from opinion leaders in the sector: 
•	 John Roberts, Penn Pharma – GMP development and manufacture of new medicines 
•	 John Harris, ABMU Health Board – NHS Perspective: Pharmacy and ABMU Health Board 
•	 Hedley Rees, PharmaFlow – Wales, Supply Chains and the opportunities 
•	 Marc Clement, Swansea University – Academic perspective: New Developments 
The panel of speakers were joined by Sian James (Health Research Wales) and Joanne Ferris 
(ABPI Cymru)  in a panel discussion to answer questions, with interactive contributions 
made by members of the audience. The Life Science Exchange then used the information 
gathered at the event to inform focus group discussions and to help for the recommendations 
presented in this report.
Output: This event resulted a number collaborative projects moving forward, including 
a GlaxoSmithKline workshop for respiratory diseases arranged by SEWAHSP and a 
Pharmaceutical Special Interest Group by MediWales.
THE PHARMACEUTICAL SECTOR IN WALES: AREAS OF FOCUS
WHEN
WHERE
WHO
“Life Science Exchange and ABPI Cymru Wales co-sponsored an event 10th February, 2014 in South 
Wales, attended by colleagues from the pharmaceutical industry, academia, Welsh Government 
and NHS Wales. The administration of the event was handled entirely by LSE seamlessly. We look 
forward to working with them further.”
– Joanne Ferris, Operations Manager, ABPI Cymru
“We have been working closely with the LSE and have found their networking, engagement 
and support to be highly valuable.  For example, they recently ran an exemplary event ‘The 
Pharmaceutical Sector in Wales - Areas of focus’.  This event was extremely well attended with 
representatives from the widest breadth of the Sector; ranging from local SMEs to the biggest global 
organisations, and yet small enough to make introductions. This has led to further collaboration with 
a workshop with GSK focusing on how we can develop joint R&D in the areas of COPD and Asthma. 
These are key areas for improving the Health and Wealth of Wales.”
– Robyn Davies, Manager, Cardiff University
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This EPSRC funded event aimed to promote ideas for innovative new technologies and methods 
for the effective management of chronic conditions in the NHS. A large group of forty delegates 
from academic, industrial and clinical backgrounds were mixed together in working groups. 
Each group considered current NHS chronic diseases management and identified the areas of 
‘unmet need’. The discussions continued to conceptualise solutions to the identified gaps, while 
identifying opportunities for new collaborative projects. The event provided a valuable forum 
for networking and ideas sharing between the numerous disciplines represented.
Output: The sandpit produced several project ideas, one of which resulted in a significant 
NISCHR/NIHR i4i grant application awaiting final stage approval.
21st May 2014
National Waterfront Museum
Life Science Exchange and ehi2
EPSRC SANDPIT EVENT: BRIDGING THE GAP
WHEN
WHERE
WHO
“I believe there is a mutual benefit for industry and healthcare from these Sandpit events. Industry 
does not always have appropriate access to those on the ground within healthcare systems, while 
healthcare workers, patients and carers are not immediately likely to turn to industry to help them 
solve an identified problem. There were clearly a few light bulb moments where participants 
suddenly understood why certain problems exist. By engaging all parties and engendering mutual 
understanding the first steps can be made on bridging this gap.”
– Dr Robin Clark, General Practitioner
“The sandpit was a great environment for freely discussing new and innovative project ideas. I was impressed 
with the range of expertise at the event, and came away from the day with some really strong connections.”
– Gavin Jones, EKF Diagnostics
“The participants at the Sandpit event have generated a number of exciting ideas regarding 
effective management of long-term conditions, affecting two-thirds of the UK population and is an 
increasing burden to the NHS. More than just a networking event; it has facilitated the formulation 
of novel and exciting ideas, where participants can develop these ideas further and work together 
through research grant applications.”
– Dr Vincent Teng, Swansea University
“There was a good deal to be positive about. I will be putting together a strong proposal for grant funding 
with the organiser, and would be interested to see more proposals coming forward as a result of the event.”
– Iain Elder, Managing Director, Pulse Medical Technologies Ltd
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EHEALTH ABMU SBRI
One of the projects the eHealth group identified was the three-year Small Business Research 
Initiative (SBRI) Catalyst Programme, also funded by the Technology Strategy Board, which 
aims to boost the research and development industry, increase commercialisation of new 
technologies and create jobs and wealth.
A project to improve Abertawe Bro Morgannwg University Health Board in partnership with 
Swansea University has received £800,000 funding towards their £950,000 project to support 
health services in Swansea, Bridgend and Neath Port Talbot through the better use of patient 
records and data. 
The SBRI came about following a simple discussion in an eHealth focus group, which was led 
by a member who had prior experience of undertaking SBRIs outside of Wales. Also at that 
meeting was the manager from the eHealth Industries Centre in Swansea University who 
subsequently identified the SBRI opportunity and engaged with ABMU. ABMU identified a 
challenge and have been extremely receptive and supportive of the SBRI process. The eHealth 
group then discussed the opportunity and many attended the two events hosted by Life 
Science Exchange with ehi2 and Welsh Government.
Several companies have subsequently been selected through an application process and have 
been awarded a contract to find the best way to use data from Swansea University’s Secure 
Anonymised Information Linkage (SAIL) databank to improve services.
Output: £800,000 grant for eHealth Small Business Research Initiative (SBRI).
11th December, 2013
Village Hotel, Swansea
Life Science Exchange, ehi2, Swansea University and ABMU Health Board
WHEN
WHERE
WHO
“The unique SAIL databank allows us a more complete picture of an individual’s health records from 
a variety of sources. This will help us better understand the health needs of our citizens and predict 
how these might change in the future. It will also help us monitor the effectiveness of measures we 
are taking now to improve public health, such as tackling childhood obesity and reducing levels of 
smoking. We expect it will also lead to a much more efficient use of resources and help us improve 
the services our patients need and improve the health and well-being of the communities we serve.”
– Professor Andrew Davies, Chairman, ABMU Health Board 
“I am absolutely delighted that we will be working with ABMU to help them to engage with 
innovative companies to deliver new ways in which the SAIL Databank can be used to support 
ABMU’s work. Our partnership with ABMU and companies that will become involved in the 
initiative will undoubtedly develop some outstanding new software products that leverage the 
power of SAIL databank for patient benefit.”
– Professor David Ford, Co-Director, SAIL
“The Welsh SBRI Innovation Catalyst Programme is a new collaboration between the Welsh 
Government and the Technology Strategy Board. By encouraging new innovative public sector 
projects, this programme will create more research and development contracts for Welsh businesses 
to bid for, helping that sector to grow and create jobs. I hope that, ultimately, SBRI will be used 
throughout the Welsh public sector for promoting innovation and providing new opportunities for 
businesses in Wales.”
– Edwina Hart, Economy Minister
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SIGNPOSTING AND BID FACILITATION
January 2014
Life Science Exchange, ABMU Health Board and AliveCor
WHEN
WHO
US company AliveCor manufacture a cost effective heart monitors that can be used with 
most mobile technology. In January 2014, the Welsh Government introduced AliveCor 
to the Life Science Exchange project team. The Life Science Exchange and Prof. Halcox of 
Swansea University identified cardiologist Dr. James Barry as an appropriate champion to 
lead a collaborative Health Technology and TeleHealth Fund bid. The Life Science Exchange 
introduced Swansea University Health Economist Prof. Ceri Phillips and Prof. Mike Gravenor, 
who were able to address important health economics and statistical analysis elements of the 
project, respectively. The Life Science Exchange team continued to contribute with input into 
the governance, project management, value creation and economic value sections of the bid as 
well as obtaining an essential letter of support from the ABMU R&D Office.
Output: In April 2014, the bid for £652,208 with £120,000 inward investment from AliveCor.
“We are pleased about the work that Morriston Hospital, Swansea University and the Welsh 
Government will be conducting with the AliveCor Heart Monitor. It is our hope that we can help give 
more patients across the world with suspected or diagnosed heart conditions, and those at risk of 
heart conditions, the ability to track their heart health anytime, anywhere.”
– Euan Thompson, President and Chief Executive, AliveCor
“Small, disruptive innovators such as AliveCor need access to networks such as the Life Science 
Exchange as they are vital to stimulate new ideas, innovations, and opportunities for collaboration. 
Working with Life Science Exchange, we were able to find the appropriate collaborators, which 
resulted in us securing a significant grant.  Further to the grant, they continue to support our inward 
investment activities from the United States into Wales.”
– Francis White, EU General Manager, AliveCor
“The Life Science Exchange provided an invaluable service while preparing a successful Health 
Technology and Telehealth Fund bid. The professional networking and administrative assistance as 
well as guidance were all very useful resources to be fortunate enough to have access to.”
– Dr. James Barry, Consultant Cardiologist and Electrophysiologist, ABMU Health Board
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PHARMACEUTICAL SUPPLY CHAIN EVENT
In June 2014, MediWales facilitated a Life Science Exchange Sandpit. The event, hosted at the 
Norgine factory in Hengoed, was attended by 23 delegates from 13 companies, universities 
and healthcare providers, all of whom are involved in pharmaceutical research, drug 
development, formulation, manufacture, packaging, trials or distribution. 
As a result of the meeting the group have identified an opportunity to work together to 
deliver and promote a full range of services to the pharmaceutical sector. Under the brand 
name Clinical Trials Services Wales, with ongoing support from MediWales, the group will 
continue to meet regularly. They are now developing a brand identity, mapping clinical trials 
services in Wales against the pharmaceutical route to market and developing marketing, 
promotional material and a programme of activity for the coming year.
Output: Clinical Trials Services Wales Pharmaceutical Special Interest Group.
June 2014
Norgine, Hengoed
Life Science Exchance, Norgine and MediWales
WHEN
WHERE
WHO
“The LSE has played an important and timely role in the flourishing life sciences sector in Wales. 
It has strongly supported the development of the Hub via the dissemination of information and 
has also fed back valuable data to the Hub from its groups. The networking and knowledge 
exchange activities the project undertakes are very valuable to the Hub and the Life Science 
sector as a whole. I look forward to working with the excellent staff in the LSE as we move into 
operational mode in the Hub.”
– Professor Chris McGuigan, Executive Chair, Welsh Life Sciences Hub
“Health Research Wales has participated in all the LSE working groups which address all aspects 
of the Life Science ecosystem in Wales.  As a result, Health Research Wales has gained many 
valuable insights into the requirement of industry and academia, which prove invaluable to the 
delivery of Health Research Wales’ services.”
– David Powell, Industry Manager, Health Research Wales
“LSE stimulated great interest in Welsh Companies wanting to do business abroad and also 
enabled us to attract a number of new clients to whom we have promoted the Enterprise Europe 
Network together with the Welsh Government’s initiatives to support local business.  Thank you 
LSE – great team work!”
– Lawson Coombes, Business Development Officer, EEN Wales
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The Life Science Exchange project strived to deliver true engagement with the Welsh life science 
sector in order to provide authentic insight into the strengths, challenges, and opportunities 
for Wales. The significant contribution made by representatives from the Welsh life sciences 
academic, industrial and clinical organisations has culminated in the detailed findings of the Life 
Science Exchange project. This report provides evidence of the appetite of these stakeholders to 
work together in order to address the challenges and take advantage of the opportunities in this 
exciting sector. Detailed conclusions have been made by each of the sector Focus Groups with a 
number of both common and unique themes across all of the groups.
 
There is a recognised need for the discussions instigated by the Life Science Exchange to continue 
into the future. In some cases, specific challenges and opportunities need to be crystallised into 
detailed proposals with specific objectives, deliverables, budgets and time-scales. A number of 
organisations have expressed the desire to maintain the momentum of their respective Focus 
Groups as Special Interest Groups operating under the Life Science Exchange brand.
 
The need for an accessible, cost-effective, up-to-date source of sector specific information relating to 
funding, regulation, international trade and market intelligence has been consistently expressed by 
the stakeholder Focus Groups. This represents a significant and ongoing opportunity to provide Welsh 
life science organisations with a valuable resource offered in addition to what is currently available.
 
The vital role that the Welsh NHS plays in providing access to clinical expertise, facilities and 
ultimately as a customer has been widely expressed. While the relationship between the NHS, 
academia and industry in Wales is considered to be a significant national strength, there is a need 
to improve the evaluation and adoption of new Welsh innovations when they can demonstrate the 
opportunity for improved patient outcomes and cost savings. Furthermore, academics and industry 
expressed a strong desire for NHS Wales to increase its level of engagement and receive clinical 
access for research and development. 
 
Significant strengths in Wales’ life sciences research activity have been demonstrated across the 
entire Welsh life sciences sector. To build upon these strengths, further support through provision 
of facilities and resources is required to close specific gaps in research capacity.
 
A key driver for future success is the ability to attract and retain highly skilled individuals. Whilst 
the University sector can focus on the development of training and, where feasible, accredited 
education in key skills, retention requires growing industrial SME clusters to provide sustainable 
employment opportunities across Wales. An all-Wales life sciences skills group consisting of key 
academics has organised discussions on delivering apprenticeships, CPD and degree-level training 
in close collaboration with Welsh Government, NHS Wales and the life sciences industrial sector.
 
The Focus Groups make a strong case for ongoing support for international trade and promotion. 
Most life science sector products occupy global markets and numerous Welsh companies sell the 
majority of their products outside of Wales. To support this activity, Focus Groups have requested 
continued or additional support to attend trade shows and conferences.
 
The output of the Life Science Exchange is a valuable body of intelligence that represents the 
collective expertise of a wide range of expert contributors. This work should serve to inform future 
policy and planning across the sector and will help to align support activities with the needs of 
companies, universities and health care providers. Specific, actionable recommendations have been 
provided in the detailed reports provided by the Life Science Exchange to the Welsh Government.  
Ultimately, this work should be used to improve innovation, health, and the wealth in Wales. 
 
Last, but not least, the Life Science Exchange process must be applauded for bringing together 
hundreds of stakeholders in a sub-sectoral approach to the Welsh National Innovation System. This 
has resulted in a multitude of collaborations, projects, inward investment opportunities, and special 
interest group formations, in addition to securing over ten times its weight in funding for Wales. 
Processes such as the Life Science Exchange should be continued to be supported by the Welsh 
Government and the process can be held up as a shining example of best practice for knowledge 
exchange to the rest of the world.
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DELIVERY TEAMS
PROJECT LEAD Professor David Ford Swansea University
FOCUS GROUP 
CHAIRS
Diagnostics
eHealth
Medical Technology
Neuroscience
Pharmaceuticals
Regenerative Medicine
Gwyn Tudor
Jon Smart
Gwyn Tudor
Jon Bisson
Brian Lee Perkins
Phil Stephens
MediWales
Swansea University
MediWales
Cardiff University
Swansea University
Cardiff University
STEERING GROUP David Ford (Chair)
Beverly Luchman
Brian Lee Perkins
Cari-Anne Quinn
Carys Thomas
Greg Baily
Gwyn Tudor
Ifan Evans
Jon Bisson
Jon Smart
Kevin Fernquest
Mike Day
Phil Stephens
Rob Garlick
Steve Bain
Steve Conlan
Terry Stubbs
Swansea University
NISCHR
Life Science Exchange
EST, Welsh Government
NISCHR
MediWales, Huntleigh
MediWales
DHSS, Welsh Government
Cardiff University
Life Science Exchange
Swansea University
Swansea University
Cardiff University
Life Science Exchange
Swansea University
Swansea University
A4B, Welsh Government
PROJECT TEAM Brian Lee Perkins
Jodie Wren
Jon Smart
Rob Garlick
Life Science Exchange
Life Science Exchange
Life Science Exchange
Life Science Exchange
MEDIWALES
PROJECT TEAM
Debbie Laubach
Gwyn Tudor
Julie Alcock 
Lucinda Dargavel Scott-Morgan
MediWales
MediWales
MediWales
MediWales
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John Harris
Joseph Ward
Judith Vincent
Joanne Ferris
Richard Greville
Louisa Harry-Thomas
Peter Taylor
Sue Bale
Alison Payne
Jonathan Hudson
Paul Mullins
Mair Griffiths
Paul Viggers
Rachel Griffiths
Tristram Evans
Mark Hardy
Kevin Fernquest
Paul Spark
Sarah Hiom
John Maisey
Khalid Hamandi
Sarah Phillips
Rose Cooper
Sarah Maddocks
Adrian Harwood 
Alistair Sloan
Andrew Quantock
Ashleigh Beckett
Bruce Caterson
Corrine Squire 
David Barrow
David Kipling
Ella Lonnen
Emma Lane
Ernest Azzopardi
Eryl Cox
Frank Sengpiel
Girish Patel
Ian Brewis
Ian Weeks
James Birchall
Jane Graves
Jemma Sedgmond
Jeremy Hall
John Aggleton
Keith Wilson
Laura Bunting
Liam Gray
Marcela Votruba
Neil Penry
Abertawe Bro Morgannwg University Health Board
Abertawe Bro Morgannwg University Health Board
Abertawe Bro Morgannwg University Health Board
ABPI
ABPI
Acuitas Medical
Acuitas Medical
Aneurin Bevan Health Board
ARP Associates
AstraZeneca
Bangor University
Bayer
Biotec Services International
Biotec Services International
Biotec-UK
Bluebay Medical
Calon Cardio
Cardiff and Vale University Health Board
Cardiff and Vale University Health Board
Cardiff and Vale University Health Board 
Cardiff and Vale University Health Board 
Cardiff and Vale University Health Board 
Cardiff Metropolitan University
Cardiff Metropolitan University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
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Neil Stephens
Nick Allen
Nick Craddock
Paul Kemp
Rachel Errington
Rachel Waddington
Richard Wise
Ryan Moseley 
Samantha Redman
Simon Hutchings
Sion Coulman
Sofia Gameiro
Stephanie Baker
Stephen Dunnett
Vanessa Davies
Vincenzo Crunelli 
John Griffiths
Simon Tyler
Alistair Ray
Judith White
Susan Peirce
Matthew Durdy
David Tosh
Chris Tackaberry
Jonathan Ryves
Raman Sakhuja
Robert Salter
Helen Delahaye
Andrew Davidson
James Davies
Julie Kennedy
Gary Dowthwaite
Jeremy Jones
Justin John
Ruth McDermott
Robyn Miles
Nanette Bartram
Huw Morgan
Andrew Guilford
Claire Banks
Richard Phillips
Martin Heaven
David Powell
Deep Khubchandani
Lydia Vitolo
Sian James
Will Krawszik
Greg Baily
Sundeep Patel
Chris Williams
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Cardiff University
Care Systems Integration
CatSci
CEDAR
CEDAR
CEDAR
Cell Therapy Catapult
University of Bath
Clinithink
Cupid Peptides
Cwm Taf Health Board
Cwm Taf Health Board
Deltohn
DTR Medical
eHealth Industries Innovation Centre (ehi2)
eHealth Industries Innovation Centre (ehi2)
EKF Diagnostics
Fulcrum Direct
GE Healthcare
GE Healthcare
GlaxoSmithKline
Glyconics Ltd
GPC Solutions Ltd
Grahame Guilford and Company
GX Group
Haemair
Health Informatics Research Unit
Health Research Wales
Health Research Wales
Health Research Wales
Health Research Wales
HPC Wales
Huntleigh Healthcare
IBM
Ig Innovations
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James Hindley
Ernest Choy
Bronwen Evans
Huw Roderick
Sue Foster
Pete Wall
Meirion Evans
Craig Story
Helen Mollart
Bryn Williams
Mark Bowman
Andrew Barker
Daniel Aeschlimann
Dave Harvey
Ahmed Izzidien
Phillip Morgan 
Rodney Gush
Nick Jones
Phil Groom
John Scandone
John Starzewski
Cheryl Way
Maynard Davies
Derek Sheader
Martin Coombes
Christopher Thomas
Helen Simpson
Lydia Owen
Nicholas Price-Jones
John Roberts
Chris Marshall
Stephen Paisey
Hedley Rees 
David Rooke
Mitch Rogers
Katie Bamsey
Beverly Wilson-Smith
John Sinden
Stuart Campbell
Natalie Allen
Andrew Thomas
Dan Philips
Robert Matthews
Greg May
Robyn Davies
Alan Woodward
Matthew Alderman
Pete Phillips
Arron Lacey
Bjorn Rodde
INDOOR Biotechnologies
Institute of Infection & Immunity
Institute of Molecular and Experimental Medicine
Invacare
Ipsen
Isca
Kimball
KODIT Databases
KODIT Databases
Kuecept
Life Science Hub
Mangar International
Matrix Biology & Tissue Repair Research Unit
Medical Connections
Medical Electronics and Signal Processing Unit
Merck Serono
Moor Instruments
MSD
Napp
Neuradaptix
Neuradaptix
NHS Wales Informatics Service
NHS Wales Informatics Service
Norgine
Novartis
Ortho Clinical Diagnostics
OSP Healthcare
OSP Healthcare
Pelican Feminine
Penn Pharma
PETIC
PETIC
PharmaFlow
ProTEM Services
Public Health England
Q-Chip
Regional Learning Partnership
Reneuron
Renishaw
Rocialle
Rogue Resolutions
Rogue Resolutions
Royal Glamorgan Hospital
Ruskinn
SEWAHSP
Simbec
SMTL
SMTL
Swansea University
Swansea University
31
OPPORTUNITIES FOR GROWTH
Charlie Archer
Cheney Drew
Chris Wright
Dareyoush Rassi
Gareth Stockman
Iain Whitaker
Ilyas Khan
Jacinta Tan
John Williams
Jonathan Mullins
Judy Jenkins
Julian Halcox
Keith Lloyd
Lawson Coombes
Lewis Francis
Marc Clement
Mark Rees
Mathilda Castagnet
Mike Lewis
Pippa Anderson 
Seydou Yao
Sian Morgan
Steve Conlan
Xianghua Xie
Zhidao Xia
Ritu Yadav
Sabarna Mukhopadhyay
Caroline Garrett
Mike Sullivan
Dylan Jones
Kirsty Martin
Clive Minihan
Kevin Smith 
Ken Hall
Molly Price-Jones
Rob Thomas
Julia Sarginson
Vanessa Davies
Angharad Penny Evans
Chris Davies
Elizabeth McCargo
Ifan Evans
Julie Cunnington-Hill
Mel Crisp
Michelle Davies
Terry Stubbs
Vashi Phare
Philip Webb
Scott Forde
Marcus Kennedy
Swansea University
Swansea University
Swansea University
Swansea University
Swansea University
Swansea University
Swansea University
Swansea University
Swansea University
Swansea University
Swansea University
Swansea University
Swansea University
Swansea University
Swansea University
Swansea University
Swansea University
Swansea University
Swansea University
Swansea University
Swansea University
Swansea University
Swansea University
Swansea University
Swansea University
SymlConnect
SymlConnect
Synergy Health
Technology Strategy Board - Regenerative Medicine
The Magstim Company
The Magstim Company
Time for Medicine
TrakCel
Triteq
Tybio
Union Chimique Belge
University of Bristol
Welsh European Funding Office
Welsh Government
Welsh Government
Welsh Government
Welsh Government
Welsh Government
Welsh Government
Welsh Government
Welsh Government
Welsh Government
Welsh Health Specilaised Services Committee
Wentwood Medical
Wipak
PARTICIPANTS
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The Academic Expertise for Business Fund 
(A4B) is managed by the Welsh Government’s 
Department for the Economy and Transport, 
and is financed by the Welsh Government and 
the European Union
